Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. - Peyrin-Biroulet, L.; Chapman, J. C.; Colombel, J.-F.; Caprioli, F.; D'Haens, G.; Ferrante, M.; Schreiber, S.; Atreya, R.; Danese, S.; Lindsay, J. O.; Bossuyt, P.; Siegmund, B.; et al. (New England Journal of Medicine, 2024)